HAINAN HAIYAO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.33 CNY | -2.35% |
|
-8.77% | -26.33% |
| Jan. 31 | Hainan Haiyao’s Antibiotic Passes Generic Evaluation | MT |
| 2023 | Hainan Haiyao's Unit Gets Nod to Become Marketing License Holder of Shuangshen Huoxue Tongluo Granules | MT |
| Sales 2021 | 2.06B 284M | Sales 2022 | 1.78B 246M | Capitalization | 5.54B 765M |
|---|---|---|---|---|---|
| Net income 2021 | -1.56B -215M | Net income 2022 | 10M 1.38M | EV / Sales 2021 | 4.67 x |
| Net Debt 2021 | 2.81B 388M | Net Debt 2022 | 3.08B 425M | EV / Sales 2022 | 4.84 x |
| P/E ratio 2021 |
-4.38
x | P/E ratio 2022 |
527
x | Employees | 2,247 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 58.32% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.35% | ||
| 1 week | -8.77% | ||
| Current month | -10.00% | ||
| 1 month | -14.18% | ||
| 3 months | -19.37% | ||
| 6 months | -26.16% | ||
| Current year | -26.33% |
1 week
3.16
3.65
1 month
3.163.95
Current year
2.904.66
1 year
2.905.59
3 years
2.906.67
5 years
2.9011.50
10 years
2.9027.64
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Hong Wang
CEO | Chief Executive Officer | 55 | 22-04-07 |
Rong Yi Xu
DFI | Director of Finance/CFO | 53 | 21-06-28 |
Jian Min Zhang
CTO | Chief Tech/Sci/R&D Officer | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xi Cheng Liu
BRD | Director/Board Member | 62 | 05-04-15 |
Duo Jia Feng
BRD | Director/Board Member | 66 | - |
Jun Hong Wang
CEO | Chief Executive Officer | 55 | 22-04-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 3.33 | -2.35% | 9,860,179 |
| 24-04-17 | 3.41 | +7.57% | 12,152,060 |
| 24-04-16 | 3.17 | -7.85% | 15,849,740 |
| 24-04-15 | 3.44 | -4.97% | 16,052,080 |
| 24-04-12 | 3.62 | -0.82% | 8,353,744 |
End-of-day quote Shenzhen S.E., April 17, 2024
More quotes
HAINAN HAIYAO CO., LTD. is a China-based company principally engaged in the research, development, manufacture and sale of medicines and medical instrument. The Companyâs main products consist of six categories, including cephalosporin series, stomach and intestine medicines, anti-tumor medicines, cochlear implant series, bulk drugs and intermediate series. The Company distributes its products in domestic market and to overseas market, with China as its main market.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -26.33% | 611M | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 000566 Stock
